Spyros Papapetropoulos
CIK 1832694 · President and CEO · last filed 2025-09-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$2.7K
Companies
4
Total Filings
16
Lifetime Open-Market Net
$49.8K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| NEUP | President and CEO | — | $3.81 | — | $0 | 3 | 2025-09-02 |
| LPCN | Director | 1,279 | $2.14 | $2.7K | $10.2K | 6 | 2025-06-05 |
| Vigil Neuroscience, Inc. (VIGL) Delisted | Chief Medical Officer | 4,000 | $8.05 | $32.2K | $9.4K | 3 | 2022-11-22 |
| Adamas Pharmaceuticals Inc (ADMS) Delisted | Director | 0 | $8.22 | $0 | $30.2K | 4 | 2021-11-24 |
Recent Filings · Page 2 of 2
16 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-04-12 | LPCN | Grant (A) | — | $0 | EDGAR |
| 2022-03-03 | Vigil Neuroscience, Inc. (VIGL) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-11-24 | Adamas Pharmaceuticals Inc (ADMS) Delisted | Mixed | −20,975 | $0 | EDGAR |
| 2021-06-04 | Adamas Pharmaceuticals Inc (ADMS) Delisted | Grant (A) | +5,000 | $0 | EDGAR |
| 2021-03-15 | Adamas Pharmaceuticals Inc (ADMS) Delisted | Buy (P) | +5,975 | $30.2K | EDGAR |
| 2020-11-24 | Adamas Pharmaceuticals Inc (ADMS) Delisted | Grant (A) | +10,000 | $0 | EDGAR |
Showing 11–16 of 16
Prev
Page 2 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.